A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

This study is investigating a new treatment for **multiple myeloma**, a type of blood cancer. The study has two parts: the first is about finding the right dose, and the second tests how well the treatment works with other drugs, *dexamethasone* and *carfilzomib*. These drugs are given through a vein (intravenously). To join, you must have tried other treatments for multiple myeloma without success. You also need good organ function and a specific genetic marker detected by a special test. You can't join if you have other conditions like certain heart diseases or infections like HIV or active hepatitis. **Key Points:** - **Study Duration**: It involves two phases, which could take several months. - **Compensation**: Participants might receive compensation for their involvement. - **Risks**: There are possible side effects due to the treatments and tests involved. This study could help find better treatments for multiple myeloma, but it requires time, multiple visits, and certain health criteria to join. If you meet the criteria and are interested, you may consider participating.